MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
September 30, 2019 03:20 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
September 27, 2019 10:15 ET
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
TLC to Present Preclinical Data on TLC178 at ESMO 2019
September 23, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019
September 23, 2019 01:00 ET
|
INNATE PHARMA
INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES CLINIQUES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019 Données préliminaires issues de STELLAR-001, l’étude de Phase I en escalade de dose...
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
September 23, 2019 01:00 ET
|
INNATE PHARMA
INNATE PHARMA ANNOUNCES CLINICAL DATA PRESENTATIONS ON IPH5401 AND MONALIZUMAB AT ESMO 2019 Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid...
Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
September 18, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been accepted for oral presentation in a proffered paper session at the...
ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress
July 31, 2019 04:14 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, July 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
January 31, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
October 20, 2018 10:45 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial...
TESARO Announces Data Presentations at ESMO 2018 Congress
October 20, 2018 01:30 ET
|
TESARO, Inc.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...